Clinical Trials | March 03, 2026
AbbVie’s Risankizumab shows strong results in hard-to-treat Crohn’s disease patients
This study evaluated a difficult-to-treat Crohn's disease patient population
This study evaluated a difficult-to-treat Crohn's disease patient population
Ivermectin Tablets USP, 3 mg, are prescription anti-parasitic medications primarily indicated for treating parasitic worm infections in humans
The LIFT-PD study will enroll 75 Parkinson’s patients experiencing apathy across 16 sites in Germany, Bulgaria, Poland and Spain
The facility is expected to become operational by FY2028-29
Desmopressin Acetate Injection is primarily used to treat central diabetes insipidus, haemophilia A, and von Willebrand disease
The decision marks a pivotal moment for the Massachusetts-based biotech giant
Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
The product addresses a market with approximately $66.8 million in annual sales as of December 2025.
Lupin attained a score of 91 out of 100, establishing itself as the leading pharmaceutical company globally
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
Subscribe To Our Newsletter & Stay Updated
